A renewed push by the central government to expand healthcare reforms and restrict costs for end users is putting pressure on margins for a growing number of Chinese drugmakers. Five Chinese drugmakers including United Laboratories International Holdings Ltd have issued profit warnings in recent weeks, citing price pressures and government policies. They are due to report earnings in March.
